• Mon, December 12, 2022

Madhu Kumar Maintained (SNDX) at Strong Buy with Increased Target to $39 on, Dec 12th, 2022

Madhu Kumar of Goldman Sachs, Maintained "Syndax Pharmaceuticals, Inc." (SNDX) at Strong Buy with Increased Target from $35 to $39 on, Dec 12th, 2022.

Madhu, nor any peers, have made any analyst calls on SNDX in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30